Immunologic Research

, Volume 66, Issue 6, pp 649–654 | Cite as

Altered expression of regulatory molecules in the skin of psoriasis

  • A. D. Sabag
  • D. Dias-Polak
  • J. Bejar
  • H. Sheffer
  • R. Bergman
  • Zahava VadaszEmail author
Original Article


The presence of T regulatory cells (Tregs) is highly required in normal skin in order to maintain immune tolerance to commensal microbes and to prevent the development of immune-mediated inflammation. Psoriasis is a chronic inflammatory skin disease in which effector T cells, namely, Th17 and their relevant pro-inflammatory cytokines are increased in peripheral blood as well as in the inflamed skin. The status of Tregs in psoriatic skin is continuously studied. In this case, CD4 + CD25high T cells and other regulatory cytokines such as IL-35 are demonstrated to be significantly decreased. Aiming to better characterize Tregs in psoriatic skin and to establish the finding of their abnormal balance, we assessed the expression of semaphorin3A and neuropilin-1 (both reported as biomarkers of Tregs). Semaphorin3A and neuropilin-1 expressing Tregs were found to be significantly decreased in psoriatic skin when compared to normal skin. These findings were supported by demonstrating the downregulation of IL-10 expression in psoriatic skin. Our findings suggest that semaphoring3A may turn to be a new promising therapeutic approach in the process of improving Treg function in psoriasis.


Psoriasis Inflammation Semaphorin3A T regulatory cells 


Compliance with ethical standards

Conflict of Interests

All authors declair that they do not have any conflict of interest regarding this manuscript.


  1. 1.
    Gisondi P, Di Mercurio M, Idolazzi L, Girolomoni G. Concept of remission in chronic plaque psoriasis. J Rheumatol Suppl. 2015;93:57–60.CrossRefGoogle Scholar
  2. 2.
    Ghoreschi K, Weigert C, Rocken M. Immunopathogenesis and role of T cells in psoriasis. Clin Dermatol. 2007;25:574–80.CrossRefGoogle Scholar
  3. 3.
    Ayala-Fontanez N, Soler DC, McCormick TS. Current knowledge on psoriasis and autoimmune diseases. Psoriasis (Auckl). 2016;6:7–32.Google Scholar
  4. 4.
    Ortega C, Fernandez-A S, Carrillo JM, Romero P, Molina IJ, Moreno JC, et al. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukoc Biol. 2009;86:435–43.CrossRefGoogle Scholar
  5. 5.
    Res PC, Piskin G, de Boer OJ, van der Loos CM, Teeling P, Bos JD, et al. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One. 2010;5:e14108.CrossRefGoogle Scholar
  6. 6.
    Teunissen MBM, Yeremenko NG, Baeten DLP, Chielie S, Spuls PI, de Rie MA, et al. The IL-17A-producing CD8+ T-cell population in psoriatic lesional skin comprises mucosa-associated invariant T cells and conventional cells. J Invest Dermatol. 2014;134:2898–7.CrossRefGoogle Scholar
  7. 7.
    Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, Abello MV, Novitskaya I, Pierson KC, et al. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol. 2009;129:79–88.CrossRefGoogle Scholar
  8. 8.
    Diani M, Altomare G, Reali E. T cell responses in psoriasis and psoriatic arthritis. Autoimmun Rev. 2015;14:286–92.CrossRefGoogle Scholar
  9. 9.
    Luan L, Ding Y, Han S, Zhang Z, Liu X. An increased proportion of circulating Th22 and Tc22 cells in psoriasis. Cell Immunol. 2014;290:196–200.CrossRefGoogle Scholar
  10. 10.
    Zhang L, Li Y, Yang X, Wei J, Zhou S, Zhao Z, et al. Charaterization of Th17 and FoxP3+ Treg cells in pediatric psoriasis patients. Scand J Immunol. 2016;83:174–80.CrossRefGoogle Scholar
  11. 11.
    Bovenschen HJ, van de Kerkhof PC, van Erp PE, Woestenenk R, Joosten I, Koenen HJ. FoxP3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin. J Invest Dermatol. 2011;131:1853–60.CrossRefGoogle Scholar
  12. 12.
    Yang L, Li B, Dang E, Jin L, Fan X, Wang G. Impaired function of regulatory T cells in patients with psoriasis is mediated by phosphorylation of STAT3. J Dermatol Sci. 2016;81:85–92.CrossRefGoogle Scholar
  13. 13.
    Gatzka M. Skin under Thf influence: how regulatory T cells work against macrophages in psoriasis. J Pathol. 2017;241:3–5.CrossRefGoogle Scholar
  14. 14.
    Sanchez Rodrigues R, Pauli ML, Neuhaus IM, Yu SS, Arron ST, Harris HW, et al. Memory regulatory T cells reside in human skin. J Clin Invest. 2014;124:1027–36.CrossRefGoogle Scholar
  15. 15.
    Wang RX, Yu CR, Dambuza IM, Mahdi RM, Dolinska MB, Sergeev YV, et al. Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat Med. 2014;20:633–41.CrossRefGoogle Scholar
  16. 16.
    Vadasz Z, Toubi E. Semaphorins: their dual role in regulating immune-mediated diseases. Clin Rev Allergy Immunol. 2014;47:17–25.CrossRefGoogle Scholar
  17. 17.
    Catalano A. The neuroimmune semaphoring-3A reduces inflammation and progression of experimental autoimmune arthritis. J Immunol. 2010;185:6373–83.CrossRefGoogle Scholar
  18. 18.
    Vadasz Z, Rainis T, Nakhleh A, Hai T, Bejar J, Halasz K, et al. The involvement of immune semaphorins in the pathogenesis of inflammatory bowel diseases. PLoS One. 2015;10:e0125860.CrossRefGoogle Scholar
  19. 19.
    Vadasz Z|, Toubi E. Semaphorin 3A- a marker for disease activity and a potential putative disease-modifying treatment in systemic lupus erythematosus. Lupus 2012; 21: 1266–1270.CrossRefGoogle Scholar
  20. 20.
    Bejar J, Kessler O, Sabag AD, Sabo E, Itzhak OB, Neufeld G, et al. Semaphorin3A: a potential therapeutic tool for lupus nephritis. Front Immunol. 2018;9:634. Scholar
  21. 21.
    Tominaga M, Takamori K. Itch and nerve fibers with special references to atopic dermatitis: therapeutic implications. J Dermatol. 2014;41:205–12.CrossRefGoogle Scholar
  22. 22.
    Ali N, Rosenblum MD. Regulatory T cells in skin. Immunology. 2017;152:372–81.CrossRefGoogle Scholar
  23. 23.
    Kotb IS, Lewis BJ, Barker RN, Ormerod AD. Differential effects of phototherapy, adalimumab and betamethasone-calcipotriol on effector and regulatory T cells in psoriasis. Br J Dermatol. 2018;179:127–35. Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • A. D. Sabag
    • 1
    • 2
  • D. Dias-Polak
    • 2
    • 3
  • J. Bejar
    • 2
    • 4
  • H. Sheffer
    • 2
    • 4
  • R. Bergman
    • 2
    • 3
  • Zahava Vadasz
    • 1
    • 2
    Email author
  1. 1.Division of Allergy & Clinical ImmunologyBnai-Zion medical CenterHaifaIsrael
  2. 2.Faculty of MedicineTechnionHaifaIsrael
  3. 3.Department of DermatologyRambam Medical CenterHaifaIsrael
  4. 4.Department of PathologyBnai-Zion Medical CenterHaifaIsrael

Personalised recommendations